All News

RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

d Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
COVID vaccine vials

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

d David Liew, FRACP

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Read Article
Stiffness,hand,MCP,joint,pain

Best of 2021: 11 Drugs That Cause Arthritis

d Jack Cush, MD

This is the #1 question I get from new consults: “How did I get arthritis?”

But as the aching are asking, they are really thinking these joint complaints must be due to something.

Read Article
FDA.approved.jpg

Best of 2021: FDA Approves Anifrolumab in SLE

d Jack Cush, MD

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  

Read Article
RheumNow Podcast square

My Podcast Gift (12.24.2021)

d Jack Cush, MD

Merry Christmas and Happy Holidays from RheumNow.



Dr. Jack Cush tells his podcast story - the genesis, keys to success and recommendations on how to get into podcasting - for teaching, practice, fun or influence.

Read Article
Best of 2021: Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025). 69% decr in VTE when levels >1068 ng/mL vs <648 ng/mL

Dr. John Cush RheumNow ( View Tweet)

Best of 2021: Colchicine suppresses MSU & CA pyrophosphate crystal activation of Nod-Like Receptor Protein 3 (NLRP3) inflammasome, thereby suppressing caspase-1 activation and the subsequent release of IL-1β and IL-18. Great review by Pillinger et al

Dr. John Cush RheumNow ( View Tweet)

Best of 2021: Metanalysis of Rituximab use in EGPA (Churg-Strauss) found 19 cohort studies, 8 case series, 18 cases, for a total of 368 EGPA patients. RTX yielded 80% w/ complete or partial remission (w/ more complete responses in pANCA+ pts) https://t.co/cIu6V6Cg8W https://t.co/Pw0ZpqqcB7

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2021: Plasmapheresis Indications : TTP, HUS, Cryoglobulinemia, Hyperviscosity, Myasthenia gravis, Goodpastures, Catastrophic APL Syn, Chr inflamm demyelinating polyneuropathy, Removal of drugs/toxins, Alveolar hemorrhage, ANCA vasculitis (questionable)

Dr. John Cush RheumNow ( View Tweet)

Best of 2021: ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/l15ZLBguxH https://t.co/7s23FeUf5g

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush tells his podcast story - the genesis, keys to success and recommendations on how to get into podcasting - for teaching, practice, fun or influence. https://t.co/l4emmdM056 https://t.co/uavfamjfI8

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/DDgu0UpZN9 https://t.co/BPlIEmRjg3

Links:

Dr. John Cush RheumNow ( View Tweet)
RESTORE trial: yet another failure for PRP injections for knee #OA. Study of 288 Knee oA over 50 years - knee pain scores of −2.1 vs −1.8 on an 11-point scale (range, 0-10) and no difference between PRP and PBO at 12 moshttps://bit.ly/3pqldWU

Dr. John Cush RheumNow ( View Tweet)

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease https://t.co/oPKErIgR3J https://t.co/mpWmfVwOsF

Links:

Dr. John Cush RheumNow ( View Tweet)
Patient Medication Preferences in PsA https://t.co/I1DXCFPNcf https://t.co/cqMGIJwLbA

Links:

Dr. John Cush RheumNow ( View Tweet)
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually! https://t.co/py6Gp8sPh8

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: Dual BAFF/APRIL Antagonist for SLE https://t.co/ktAhM2C0i7

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: AstraZeneca announced that Saphnelo (anifrolumab - Type 1 IFN receptor MAb) was recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus https://t.co/Aiem2P4Em0

Links:

Dr. John Cush RheumNow ( View Tweet)

RA Panel: Safety, Multimorbidities, Vaccination and the Weather https://t.co/0N212LKSzK

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: Steroids in RA Patients 65 and Older https://t.co/5cHMfSRSAi

Links:

Dr. John Cush RheumNow ( View Tweet)

×